Select Page

This year, EpiVax was awarded $243,561 in Total Direct and Indirect Funding to support the development of their unique HIV vaccine platform (de-tolerized anti-Dec205). The total amount awarded to date is $797,855 in Direct and Indirect costs, to further this aspect of the GAIA Vaccine development program.